Cargando…

First-Line Pembrolizumab Mono- or Combination Therapy of Non-Small Cell Lung Cancer: Baseline Metabolic Biomarkers Predict Outcomes

SIMPLE SUMMARY: Positron-emission tomography/computed tomography (PET/CT) is used for staging of non-small cell lung cancer (NSCLC) and can help to estimate prognosis in patients treated with immune checkpoint inhibitor (ICI) therapy. Most available data in that field were derived from cohorts treat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lang, David, Ritzberger, Linda, Rambousek, Vanessa, Horner, Andreas, Wass, Romana, Akbari, Kaveh, Kaiser, Bernhard, Kronbichler, Jürgen, Lamprecht, Bernd, Gabriel, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8656760/ https://www.ncbi.nlm.nih.gov/pubmed/34885206 http://dx.doi.org/10.3390/cancers13236096

Ejemplares similares

Serum Tumor Marker Dynamics as Predictive Biomarkers in NSCLC Chemo-Immunotherapy and Mono-Immunotherapy Maintenance: A Registry-Based Descriptive Study
por: Lang, David, et al.
Publicado: (2020)

Therapy Line and Associated Predictors of Response to PD-1/PD-L1-Inhibitor Monotherapy in Advanced Non-small-Cell Lung Cancer: A Retrospective Bi-centric Cohort Study
por: Lang, David, et al.
Publicado: (2019)

Computed Tomography Findings as Determinants of Local and Systemic Inflammation Biomarkers in Interstitial Lung Diseases: A Retrospective Registry-Based Descriptive Study
por: Lang, David, et al.
Publicado: (2021)

Sex-Based Clinical Outcome in Advanced NSCLC Patients Undergoing PD-1/PD-L1 Inhibitor Therapy—A Retrospective Bi-Centric Cohort Study
por: Lang, David, et al.
Publicado: (2021)

Clinical, imaging, and blood biomarkers to assess 1-year progression risk in fibrotic interstitial lung diseases—Development and validation of the honeycombing, traction bronchiectasis, and monocyte (HTM)-score
por: Shao, Guangyu, et al.
Publicado: (2022)

Computed tomography findings as determinants of pulmonary function tests in fibrotic interstitial lung diseases—Network-analyses and multivariate models
por: Lang, David, et al.
Publicado: (2020)

Complications of CT-guided transthoracic lung biopsy: A short report on current literature and a case of systemic air embolism
por: Lang, David, et al.
Publicado: (2018)

Durvalumab after Sequential High Dose Chemoradiotherapy versus Standard of Care (SoC) for Stage III NSCLC: A Bi-Centric Trospective Comparison Focusing on Pulmonary Toxicity
por: Wass, Romana, et al.
Publicado: (2022)

Adherence to inhaled therapy and its impact on chronic obstructive pulmonary disease (COPD)
por: Humenberger, Magdalena, et al.
Publicado: (2018)

Potential influence of automated volumetry on treatment response classifications in lung cancer lesions
por: Akbari, Kaveh, et al.
Publicado: (2014)

Quality of Life and Limitations in Daily Life of Stable COPD Outpatients in a Real-World Setting in Austria – Results from the CLARA Project
por: Horner, Andreas, et al.
Publicado: (2020)

Development and validation of the Salzburg COPD-screening questionnaire (SCSQ): a questionnaire development and validation study
por: Weiss, Gertraud, et al.
Publicado: (2017)

Mono kick start
por: Schönig, Hans-Jürgen
Publicado: (2004)

Baseline Absolute Lymphocyte Count and ECOG Performance Score Are Associated with Survival in Advanced Non-Small Cell Lung Cancer Undergoing PD-1/PD-L1 Blockade
por: Huemer, Florian, et al.
Publicado: (2019)

Association of the Metabolic Score Using Baseline FDG-PET/CT and dNLR with Immunotherapy Outcomes in Advanced NSCLC Patients Treated with First-Line Pembrolizumab
por: Seban, Romain-David, et al.
Publicado: (2020)

Pembrolizumab as first-line treatment for metastatic uveal melanoma
por: Rossi, Ernesto, et al.
Publicado: (2019)

Physical Activity, Depression and Quality of Life in COPD – Results from the CLARA II Study
por: Horner, Andreas, et al.
Publicado: (2023)

Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation
por: Cortellini, Alessio, et al.
Publicado: (2020)

Pembrolizumab
por: Khoja, Leila, et al.
Publicado: (2015)

A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with Pembrolizumab
por: Awada, Gil, et al.
Publicado: (2021)

Keynote 42: Pembrolizumab, PD-L1, and where to draw the line
por: Isaacs, James, et al.
Publicado: (2020)

Cost-effectiveness of Pembrolizumab as a Second-Line Therapy for Hepatocellular Carcinoma
por: Chiang, Chi-leung, et al.
Publicado: (2021)

CT based radiomic approach on first line pembrolizumab in lung cancer
por: Zerunian, Marta, et al.
Publicado: (2021)

Comparative evaluation of baseline characteristics of HIV mono infected and HIV/HBV co infected cohort in eastern India
por: Sarkar, Jayeeta, et al.
Publicado: (2014)

Mono
por: Wu, Cheng'en, ca. 1500-ca. 1582
Publicado: (1945)

Subjects with Discordant Airways Obstruction: Lost between Spirometric Definitions of COPD
por: Lamprecht, Bernd, et al.
Publicado: (2011)

Is spirometry properly used to diagnose COPD? Results from the BOLD study in Salzburg, Austria: a population-based analytical study
por: Lamprecht, Bernd, et al.
Publicado: (2013)

The theory of extensive form games
por: Alós-Ferrer, Carlos, et al.
Publicado: (2016)

Pembrolizumab for all
por: Kim, Myung S., et al.
Publicado: (2022)

Dramatic Response to First Line Single Agent Pembrolizumab in Anaplastic Thyroid Carcinoma
por: Spalart, Valérie, et al.
Publicado: (2019)

Optimal Management of First-Line Advanced Renal Cell Carcinoma: Focus on Pembrolizumab
por: Singh, Abhay, et al.
Publicado: (2020)

Pembrolizumab: A reliable second‐line treatment option for advanced esophageal cancer
por: Zheng, Li, et al.
Publicado: (2022)

Intracellular Mono-ADP-Ribosylation in Signaling and Disease
por: Bütepage, Mareike, et al.
Publicado: (2015)

Mono-jet, Mono-V searches in ATLAS and CMS
por: Sharma, Varun
Publicado: (2021)

Mono-Higgs, Mono-top searches in ATLAS and CMS
por: Toscani, Mariana
Publicado: (2021)

First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy
por: Zhou, Yixin, et al.
Publicado: (2019)

Impact of exercise training and supplemental oxygen on submaximal exercise performance in patients with COPD
por: Neunhäuserer, Daniel, et al.
Publicado: (2020)

Update on the role of pembrolizumab in patients with unresectable or metastatic colorectal cancer
por: Wookey, Vanessa, et al.
Publicado: (2021)

MONO 1001
por: Pacquet, J Y, et al.
Publicado: (2002)

Mono-pharmacy
por: Gailliard,
Publicado: (1890)

Cannot write session to /tmp/vufind_sessions/sess_qshv1p2pmdai716350d89bnmih